Form 4: CytomX Therapeutics Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Jeffrey B Landau, Chief Business Officer of CytomX Therapeutics, sold shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- On March 19, 2024, Jeffrey B Landau, Chief Business Officer of CytomX Therapeutics, sold 6,562 shares of common stock at a price of $2.0855 per share.
- The sale was executed to satisfy tax or other government withholding obligations related to the vesting of restricted stock units.
- Following the transaction, Landau directly owns 110,060 shares of CytomX Therapeutics, which includes 64,802 restricted stock units.
- Landau also indirectly owns 4,500 shares through a Fidelity Traditional IRA and 3,180 shares through a Schwab ROTH IRA.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction (sale of shares for tax obligations) and doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential sentiment.
Stakeholder Impact
- The sale of shares by an officer could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
Key Dates
| Date | Description |
|---|---|
| 03/19/2024 | Date of stock sale transaction. |
| 03/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.